Not sure how you gather that BINX are ahead of Lumos diagnostics?
Binx annual revenue for 2023 was $15M USD which is on par with LDX.
They have deals with similar distributors as LDX does.
They deal in the same space, however LDX provides them manufacturing services. If they were ahead of LDX, they would do that in house.
Their $65million in their recent funding and a total of $169Million to date via multiple funding rounds. The $65M is on par with LDX's IPO funding.
Binx has 2 main products in market - their IO platform which LDX has distribution rights for and at home STI testing kits. The BINX IO is CLIA waived as its an easier test to use and more likely simpler to clear via the CLIA waiver. Febridx is a little more complex hence why it isn't currently CLIA waived.
Lumos provides manufacturing work to multiple parties including Binx, has their 2 main products in market and developing tests ongoing for other companies. Their Leelu reader is also used via multiple companies for verification studies each year.
Face value, they are on par, but I would put LDX an inch ahead given the multiple channels for revenue.
Add to My Watchlist
What is My Watchlist?
